Utilized for osteoporosis to manage bone density and support fracture risk reduction.
Mechanism of Action
Alendronate binds to hydroxyapatite crystals in the bone, where it inhibits the activity of osteoclasts. This slows down bone resorption and allows for increased bone mineralization and density.
Route of Administration
Oral
Onset Time
3–6 months
Duration
Weeks to years (terminal half-life over 10 years)
Contraindications
Esophageal abnormalities, Inability to sit upright for 30 minutes, Hypocalcemia, Severe renal impairment
Severe Adverse Events
Osteonecrosis of the jaw, Esophageal ulceration, Atypical femur fractures — requires immediate medical attention
Information related to Alendronate is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
